CRYSTALLOGRAPHIC STUDIES OF NOVEL PROTEIN SYNTHESIS
新型蛋白质合成的晶体学研究
基本信息
- 批准号:7726260
- 负责人:
- 金额:$ 1.1万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2008
- 资助国家:美国
- 起止时间:2008-09-18 至 2009-06-30
- 项目状态:已结题
- 来源:
- 关键词:AddressAffinityAnti-Bacterial AgentsAnti-Infective AgentsAntibioticsBindingChemicalsClassComplexComputer Retrieval of Information on Scientific Projects DatabaseFundingGoalsGrantHaloarcula marismortuiHousingInstitutionPharmaceutical PreparationsPharmacologic SubstanceProcessProtein BiosynthesisRangeResearchResearch PersonnelResolutionResourcesRibosomesSourceStagingStructureUnited States National Institutes of Healthbacterial resistancebasedesigndrug discoveryimprovedinhibitor/antagonistnovelrib bone structuresmall molecule
项目摘要
This subproject is one of many research subprojects utilizing the
resources provided by a Center grant funded by NIH/NCRR. The subproject and
investigator (PI) may have received primary funding from another NIH source,
and thus could be represented in other CRISP entries. The institution listed is
for the Center, which is not necessarily the institution for the investigator.
Rib-X Pharmaceuticals, Inc. is an early stage pharmaceutical company whose stated goal is to address the difficulties presented by increasing bacterial resistance against current antibacterial agents by discovering novel chemical classes of anti-infectives that target the
ribosome. In order to shorten the drug discovery process, we are employing a structure-based design strategy utilizing high resolution crystal structures of the 50S ribosome from Haloarcula marismortui complexed with small molecule inhibitors. These molecules range from known antibiotic leads, to compounds designed and synthesized in-house based on our previous structural results. The resulting structural information will serve as a guide for further compound designs that aim to increase binding affinity and improve overall drug-like qualities.
这个子项目是许多研究子项目中的一个
由NIH/NCRR资助的中心赠款提供的资源。子项目和
研究者(PI)可能从另一个NIH来源获得了主要资金,
因此可以在其他CRISP条目中表示。所列机构为
研究中心,而研究中心不一定是研究者所在的机构。
Rib-X Pharmaceuticals,Inc.是一家早期的制药公司,其既定目标是通过发现新的化学类别的抗感染药物来解决增加细菌对当前抗菌剂的耐药性所带来的困难,
核糖体 为了缩短药物发现过程,我们采用了基于结构的设计策略,利用来自Haloarcula marismortui的50 S核糖体与小分子抑制剂复合的高分辨率晶体结构。 这些分子的范围从已知的抗生素先导化合物到基于我们以前的结构结果内部设计和合成的化合物。 所得到的结构信息将作为进一步化合物设计的指导,旨在增加结合亲和力和改善整体药物样质量。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Joseph Ippolito其他文献
Joseph Ippolito的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Joseph Ippolito', 18)}}的其他基金
THE DISCOVERY OF NOVEL ANTIBIOTICS THROUGH HIGH RESOLUTION STUDIES OF THE LARGE
通过大规模高分辨率研究发现新型抗生素
- 批准号:
8363395 - 财政年份:2011
- 资助金额:
$ 1.1万 - 项目类别:
HIGH RESOLUTION STUDIES OF THE LARGE RIBOSOMAL SUBUNIT BOUND TO NEWLY DESIGNED I
与新设计的 I 结合的大核糖体亚基的高分辨率研究
- 批准号:
8170648 - 财政年份:2010
- 资助金额:
$ 1.1万 - 项目类别:
THE DISCOVERY OF NOVEL ANTIBIOTICS THROUGH HIGH RESOLUTION STUDIES OF THE LARGE
通过大规模高分辨率研究发现新型抗生素
- 批准号:
8170611 - 财政年份:2010
- 资助金额:
$ 1.1万 - 项目类别:
CRYSTALLOGRAPHIC STUDIES OF NOVEL PROTEIN SYNTHESIS
新型蛋白质合成的晶体学研究
- 批准号:
7957249 - 财政年份:2009
- 资助金额:
$ 1.1万 - 项目类别:
CRYSTALLOGRAPHIC STUDIES OF NOVEL PROTEIN SYNTHESIS
新型蛋白质合成的晶体学研究
- 批准号:
7602327 - 财政年份:2007
- 资助金额:
$ 1.1万 - 项目类别:
CRYSTALLOGRAPHIC STUDIES OF NOVEL PROTEIN SYNTHESIS
新型蛋白质合成的晶体学研究
- 批准号:
7358888 - 财政年份:2006
- 资助金额:
$ 1.1万 - 项目类别:
CRYSTALLOGRAPHIC STUDIES OF NOVEL PROTEIN SYNTHESIS
新型蛋白质合成的晶体学研究
- 批准号:
7182480 - 财政年份:2005
- 资助金额:
$ 1.1万 - 项目类别:
相似海外基金
Construction of affinity sensors using high-speed oscillation of nanomaterials
利用纳米材料高速振荡构建亲和传感器
- 批准号:
23H01982 - 财政年份:2023
- 资助金额:
$ 1.1万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Affinity evaluation for development of polymer nanocomposites with high thermal conductivity and interfacial molecular design
高导热率聚合物纳米复合材料开发和界面分子设计的亲和力评估
- 批准号:
23KJ0116 - 财政年份:2023
- 资助金额:
$ 1.1万 - 项目类别:
Grant-in-Aid for JSPS Fellows
Platform for the High Throughput Generation and Validation of Affinity Reagents
用于高通量生成和亲和试剂验证的平台
- 批准号:
10598276 - 财政年份:2023
- 资助金额:
$ 1.1万 - 项目类别:
Development of High-Affinity and Selective Ligands as a Pharmacological Tool for the Dopamine D4 Receptor (D4R) Subtype Variants
开发高亲和力和选择性配体作为多巴胺 D4 受体 (D4R) 亚型变体的药理学工具
- 批准号:
10682794 - 财政年份:2023
- 资助金额:
$ 1.1万 - 项目类别:
Collaborative Research: DESIGN: Co-creation of affinity groups to facilitate diverse & inclusive ornithological societies
合作研究:设计:共同创建亲和团体以促进多元化
- 批准号:
2233343 - 财政年份:2023
- 资助金额:
$ 1.1万 - 项目类别:
Standard Grant
Collaborative Research: DESIGN: Co-creation of affinity groups to facilitate diverse & inclusive ornithological societies
合作研究:设计:共同创建亲和团体以促进多元化
- 批准号:
2233342 - 财政年份:2023
- 资助金额:
$ 1.1万 - 项目类别:
Standard Grant
Molecular mechanisms underlying high-affinity and isotype switched antibody responses
高亲和力和同种型转换抗体反应的分子机制
- 批准号:
479363 - 财政年份:2023
- 资助金额:
$ 1.1万 - 项目类别:
Operating Grants
Deconstructed T cell antigen recognition: Separation of affinity from bond lifetime
解构 T 细胞抗原识别:亲和力与键寿命的分离
- 批准号:
10681989 - 财政年份:2023
- 资助金额:
$ 1.1万 - 项目类别:
CAREER: Engineered Affinity-Based Biomaterials for Harnessing the Stem Cell Secretome
职业:基于亲和力的工程生物材料用于利用干细胞分泌组
- 批准号:
2237240 - 财政年份:2023
- 资助金额:
$ 1.1万 - 项目类别:
Continuing Grant
ADVANCE Partnership: Leveraging Intersectionality and Engineering Affinity groups in Industrial Engineering and Operations Research (LINEAGE)
ADVANCE 合作伙伴关系:利用工业工程和运筹学 (LINEAGE) 领域的交叉性和工程亲和力团体
- 批准号:
2305592 - 财政年份:2023
- 资助金额:
$ 1.1万 - 项目类别:
Continuing Grant